ORPHA:314684
Primary bone lymphoma
Publications
707
86.1th percentile
Trials
0
Interventional, condition-specific
Researchers
1,107
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
Primary bone lymphoma is a rare lymphoid hemopathy defined as single or multiple tumors in the bone, not associated with infringement or violation of other extranodal malignant lymph nodes outside the area. It usually presents with bone pain, nerve compression, a palpable mass or fracture, while systemic features (fever, night sweats, fatigue, loss of appetite, weight loss) are not common.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017814
- UMLS:C1332582
- NCIT:C6620
Additional Mondo synonyms (4)
bone tissue lymphoma · lymphoma of bone tissue · primary lymphoma of bone · primary lymphoma of the bone
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
707 matched papers (332 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
707
707 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
707 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
332 in the last 10 years · high confidence · 86.1th percentile (publications denominator)
Phrase hits: 707 · MeSH hits: 0
Who's working on it?
1,107
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Li X6 papers · 2025
*Department of Oncology, The First Affiliated Hospital Zhengzhou University, Zhengzhou, China Departments of †Hematopathology ‡Radiation Oncology §Bioinformatics and Computational Biology ∥Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center #Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX ¶Department of Pathology, Harvard University Medical School, Boston, MA.
Papers in Europe PMC - 02Li J4 papers · 2024
Department of Orthopaedics, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Papers in Europe PMC - 03Chen L3 papers · 2025
Department of Neurology, Peking University Third Hospital, Beijing 100191, China.
Papers in Europe PMC - 04Jiang L3 papers · 2025
Department of Pathology, Mayo Clinic, Jacksonville, FL, USA.
Papers in Europe PMC - 05Liu X3 papers · 2025
Department of Pathology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China.
Papers in Europe PMC - 06Zhang M3 papers · 2023
Department of Hematology, Fuyang People's Hospital (The Affiliated Fuyang People's Hospital of Anhui Medical University), Fuyang City, Anhui Province, China.
Papers in Europe PMC - 07Zhang Z3 papers · 2025
Hainan General Hospital (Hainan Medical University Hainan Hospital), Haikou, China.
Papers in Europe PMC - 08Agrawal N2 papers · 2021
The Feinstein Institute for Medical Research, Manhasset, NY 11030, USA.
Papers in Europe PMC - 09Arana Yi C2 papers · 2019
University of New Mexico Comprehensive Cancer Center Albuquerque New Mexico.
Papers in Europe PMC - 10Attou R2 papers · 2024
Department of Intensive Care Unit, C.H.U Brugmann, Brussels, Belgium.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Primary bone lymphoma" OR "bone tissue lymphoma" OR "lymphoma of bone tissue" OR "lymphoma of the bone tissue" OR "primary lymphoma of bone" OR "primary lymphoma of the bone"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Primary bone lymphoma" OR "bone tissue lymphoma" OR "lymphoma of bone tissue" OR "lymphoma of the bone tissue" OR "primary lymphoma of bone" OR "primary lymphoma of the bone"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T13:12:04.230Z